Retatrutide (Reta) Australia

Retatrutide Australia. Retatrutide is the most powerful of the metabolic research peptides. What the trials report is large reductions in body weight, alongside lower appetite, better blood sugar and insulin control, and less fat stored in the liver. The weight reductions are the largest published for any compound in the GLP-1 family, which is why it has become the one everything else gets measured against.

How it does it. Most peptides in this family act on a single receptor. Retatrutide acts on three at once: GLP-1, GIP and glucagon. Those are the docking points for the gut and pancreatic signals that regulate appetite, blood sugar and how much energy the body burns. Hitting all three on one molecule is what separates it from tirzepatide, which acts on two, and semaglutide, which acts on one.

The vial. Independently HPLC-tested above 99% purity by Janoshik, with the certificate of analysis published on this page and in the lab-reports library. That is the measured number, not a marketing figure, and it carries a verifiable Janoshik key. Supplied in 10 mg, 15 mg, 20 mg and 30 mg freeze-dried vials, dispatched from Australia, AUD pricing. Supplied strictly for in-vitro and laboratory research use only. Not for human or animal consumption, not a therapeutic good, not TGA-approved.

Also known as reta. Reta, or reta peptide, is the shorthand most Australian research listings use for retatrutide. If you are comparing reta prices, or searching reta 30mg specifically, this is the same compound: the vials above are 10 mg, 15 mg, 20 mg and 30 mg, each with its own Janoshik certificate.

Retatrutide (CAS 2381089-83-2; molecular formula C221H342N46O68, average molecular weight ≈ 4731 g/mol) is a 39-residue synthetic peptide referenced in research literature as LY3437943. Its backbone carries non-standard residues — aminoisobutyric-acid substitutions and an α-methyl-leucine that resist enzymatic degradation, plus a C20 fatty-diacid conjugate that supports albumin binding — and terminates in a C-terminal amide.

In receptor and pathway research it is characterised as a balanced triple agonist of three class B G-protein-coupled receptors: the GLP-1 receptor, the GIP (glucose-dependent insulinotropic polypeptide) receptor, and the glucagon receptor. The discovery and receptor-pharmacology profile of this single-peptide triple agonist were reported by Coskun and colleagues (Cell Metabolism, 2022), who characterised its balanced glucagon- and GLP-1-receptor activity alongside greater GIP-receptor activity.

The first-in-patient pharmacokinetic work — the profile behind the extended half-life that supports once-weekly research dosing schedules — was reported by Urva and colleagues (The Lancet, 2022). Retatrutide extends the multi-agonist concept beyond tirzepatide (a GLP-1 / GIP dual agonist) by adding glucagon-receptor activity on the same peptide backbone, which is why it is frequently compared with tirzepatide in receptor-pharmacology research.

The triple-agonist profile is the reason retatrutide is referenced across both incretin-pathway and energy-homeostasis research literature; it is used as a reference multi-agonist ligand for probing the downstream signalling crosstalk between the incretin and glucagon pathways.

The information provided here is a research-reference summary only. Elite AU Peptides makes no medical, therapeutic, weight-loss, body-composition, or human-use claim about this product. Retatrutide is not TGA-approved, is not a therapeutic good, and is supplied strictly for in-vitro and laboratory research use only. Researchers should consult the primary peer-reviewed literature for receptor-binding affinities, pharmacokinetic data, and protocol-specific reference values.

Reconstitute the lyophilised retatrutide vial with bacteriostatic water for laboratory handling. Add the diluent slowly down the vial wall and swirl gently rather than shaking. The required volume depends on your research protocol and target working concentration — a 10 mg vial reconstituted in 2 mL of bacteriostatic water yields a 5 mg/mL working stock.

Store the lyophilised powder at −20°C, desiccated and protected from light; once reconstituted, store refrigerated at 2–8°C and use within the documented research window, or aliquot and freeze to avoid repeated freeze-thaw cycles. Tamper-evident packaging; the batch label is the canonical reference for the certificate of analysis published in the lab-reports library.

Shop bacteriostatic water

Australia only. Free shipping over $100. Orders placed before 12pm AEST are dispatched the same business day from Australia.

30-day returns on unused product in original packaging, with prior approval.